http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018143511-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe8aeb098a3b81976f3800d2c748b88c
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
filingDate 2017-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8684a180cda00816c1ef94807116ad49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8e02bd3cd5ba50dc828db8a39ded220
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf6b2c49bd9a6eca082fcfd4f879db46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30862ef04f41c499584b33f40e33574c
publicationDate 2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2018143511-A1
titleOfInvention Oral sustained-release triple tablet containing pregabalin
abstract Disclosed is a sustained-release three-layer tablet appropriate for administration once a day.
priorityDate 2017-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE41920-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5563175-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20080073989-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5486971
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399472

Total number of triples: 38.